Vactech is a leading brand specializing in R&D services in the preclinical vaccine development, diagnostics, and biobanking fields. With a focus on modern technologies and contract-type research, Vactech is dedicated to delivering innovative solutions for defined purposes. Founded in 2001, the company's mission is to select and pursue research with the potential for both academic and commercial success.

Vactech's flagship project is a patented enterovirus-based preventive Type 1 Diabetes (T1D) vaccine, designed to tackle the rapidly increasing global prevalence of T1D. This revolutionary vaccine, similar to the widely-used polio vaccine, is projected to generate significant revenue exceeding $5 billion in the US and EU within the first 10 years of its introduction. Moreover, it has the potential to prevent a range of enterovirus-related diseases, including common cold, otitis media, and central nervous system and heart infections.

Utilizing a vast biobank of over 200,000 children screened for genetic predisposition to T1D, Vactech's vaccine is backed by solid research. The company also leverages the Virus Like Particle (VLP) technology in its IMAVAC™ product line, ensuring the development of effective vaccines, immunomodulators, and diagnostic applications. As a privately owned company, Vactech benefits from quick decision-making and operates with a light organizational structure, collaborating with both industrial and academic partners.

Notably, Vactech has formed a strategic partnership with Provention Bio, Inc., primarily focusing on the preventive Type 1 Diabetes vaccine and related applications. Located in Tampere, Finland, Vactech is committed to advancing healthcare through groundbreaking research and licensing of vaccines and novel technologies. Contact Vactech today to learn more about their cutting-edge solutions